Item 9 Labs (INLB) EBIT (2016 - 2023)
Item 9 Labs' EBIT history spans 12 years, with the latest figure at -$3.0 million for Q2 2023.
- For Q2 2023, EBIT rose 22.92% year-over-year to -$3.0 million; the TTM value through Jun 2023 reached $9.4 million, up 166.18%, while the annual FY2022 figure was $6.5 million, 216.58% up from the prior year.
- EBIT reached -$3.0 million in Q2 2023 per INLB's latest filing, down from -$1.3 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $15.3 million in Q3 2022 to a low of -$8.2 million in Q3 2019.
- Average EBIT over 5 years is -$676017.1, with a median of -$1.0 million recorded in 2019.
- Peak YoY movement for EBIT: tumbled 2422.57% in 2019, then skyrocketed 377.63% in 2022.
- A 5-year view of EBIT shows it stood at -$1.2 million in 2019, then soared by 69.54% to -$366089.0 in 2020, then plummeted by 483.09% to -$2.1 million in 2021, then increased by 25.73% to -$1.6 million in 2022, then crashed by 87.08% to -$3.0 million in 2023.
- Per Business Quant, the three most recent readings for INLB's EBIT are -$3.0 million (Q2 2023), -$1.3 million (Q1 2023), and -$1.6 million (Q4 2022).